Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Boston Trust Walden Corp

Boston Trust Walden Corp increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 874,081 shares of the biopharmaceutical company’s stock after purchasing an additional 191,465 shares during the period. Boston Trust Walden Corp owned 0.69% of Halozyme Therapeutics worth $41,790,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in HALO. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at about $29,000. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares during the last quarter. Toth Financial Advisory Corp purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $65,000. Finally, Park Place Capital Corp increased its position in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 1,209 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on HALO shares. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Halozyme Therapeutics Stock Down 0.6 %

Shares of NASDAQ:HALO opened at $56.28 on Tuesday. The company has a market capitalization of $7.16 billion, a price-to-earnings ratio of 18.64, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. The company has a 50 day moving average of $50.82 and a two-hundred day moving average of $54.33. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.